Cancer Management and Research (Jul 2023)
Cell Cycle-Related lncRNAs as Innovative Targets to Advance Cancer Management
Abstract
Xiao-Ru Liang,1,* Yan-Fei Liu,1,* Feng Chen,2 Zhi-Xia Zhou,3 Li-Jie Zhang,1 Zhi-Juan Lin1 1Key Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, School of Basic Medical Sciences, Weifang Medical University, Weifang, People’s Republic of China; 2Department of General Surgery, Weifang Traditional Chinese Hospital, Weifang, Shandong, People’s Republic of China; 3Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhi-Juan Lin; Li-Jie Zhang, Key Laboratory of Immune Microenvironment and Inflammatory Disease Research in Universities of Shandong Province, School of Basic Medical Sciences, Weifang Medical University, Weifang, People’s Republic of China, Tel +86-536-8462530, Email [email protected]; [email protected]: Long non-coding RNAs (lncRNAs) are non-coding RNAs (ncRNAs) longer than 200nt. They have complex biological functions and take part in multiple fundamental biological processes, such as cell proliferation, differentiation, survival and apoptosis. Recent studies suggest that lncRNAs modulate critical regulatory proteins involved in cancer cell cycle, such as cyclin, cell cycle protein-dependent kinases (CDK) and cell cycle protein-dependent kinase inhibitors (CKI) through different mechanisms. To clarify the role of lncRNAs in the regulation of cell cycle will provide new ideas for design of antitumor therapies which intervene with the cell cycle progression. In this paper, we review the recent studies about the controlling of lncRNAs on cell cycle related proteins such as cyclin, CDK and CKI in different cancers. We further outline the different mechanisms involved in this regulation and describe the emerging role of cell cycle-related lncRNAs in cancer diagnosis and therapy.Keywords: cyclin, cyclin-CDK, CDK inhibitors, lncRNA
